<DOC>
	<DOC>NCT01106014</DOC>
	<brief_summary>The AC-065A302 GRIPHON study is an event-driven Phase 3 study to demonstrate the effect of ACT-293987 on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.</brief_summary>
	<brief_title>Selexipag (ACT-293987) in Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Male and female patients 1875 years old, with symptomatic PAH PAH belonging to the following subgroups of the updated Dana Point Clinical Classification Group 1 (Idiopathic, or Heritable, or Drug or toxin induced, or Associated (APAH) with Connective tissue disease, Congenital heart disease with simple systemictopulmonary shunt at least 1 year after surgical repair, or HIV infection) Documented hemodynamic diagnosis of PAH by right heart catheterization, performed at any time prior to Screening Six minute walk distance (6MWD) between 50 and 450 m at Screening within 2 weeks prior to the Baseline Visit Signed informed consent Patients with pulmonary hypertension (PH) in the Updated Dana Point Classification Groups 25, and PAH Group 1 subgroups that are not covered by the inclusion criteria Patients who have received prostacyclin or its analogs within 1 month before Baseline Visit, or are scheduled to receive any of these compounds during the trial Patients with moderate or severe obstructive lung disease Patients with moderate or severe restrictive lung disease Patients with moderate or severe hepatic impairment (ChildPugh B and C) Patients with documented left ventricular dysfunction Patients with severe renal insufficiency Patients with BMI &lt;18.5 Kg/m2 Patients who are receiving or have been receiving any investigational drugs within 1 month before the Baseline Visit Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements, in particular with 6MWT Recently conducted or planned cardiopulmonary rehabilitation program based on exercise training Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements Life expectancy less than 12 months Females who are lactating or pregnant or plan to become pregnant during the study Known hypersensitivity to any of the excipients of the drug formulations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>PAH</keyword>
</DOC>